HLB Genex Holds 40.71% Stake in HLB Pep... Internal Transfer of CBs and Minor Open-Market Purchase
As of May 29, 2026, HLB Genex holds a 40.71% stake in HLB Pep, down 0.28%p from 40.99% in the previous report. This decrease is due to an increase in total outstanding shares from 9,293,398 to 9,376,439, which may slightly dilute existing shareholder value.
Internal transfer of convertible bonds among special relations: HLB Biostep acquired 279,134 convertible bonds (face value approx. 2 billion KRW) from HLB Life Science. This is a portfolio adjustment among affiliates and does not affect control.
Special relation Sim Kyeong-jae purchased 2,170 shares on the open market (approx. 14 million KRW), a minor increase with no material impact on management control.
As the largest shareholder, HLB Genex disclosed its intent to exercise influence over management: appointment/dismissal of executives, changes to articles, capital changes, dividend decisions, mergers/demergers, business transfers, etc.
Material contracts: HLB holds call option agreements with Grace New Technology Fund 75, Nomad No. 6 Fund, and T-Whale Co., covering a total of 1,004,883 shares (8.87% stake).
[AI Comprehensive Analysis]This is a routine change in shareholding, involving an internal transfer of convertible bonds and a minor open-market purchase. The impact on stock price or enterprise value is limited. While the slight decrease in stake due to increased outstanding shares could be a dilution factor, the scale is negligible, resulting in low practical risk.